Decision/Other
Adopted
National Medical Products Administration accepts marketing application for CagriSema
China's drug regulator accepted Novo Nordisk's marketing application for CagriSema, a once-weekly combination injection, for long-term weight management, moving the product closer to approval in China.
Actors and targets
Targets 卡瑞林肽司美格鲁肽注射液（CagriSema）item
Source
其新药卡瑞林肽司美格鲁肽注射液（CagriSema）用于长期体重管理的上市申请获国家药监局受理
Extracted detail
Fields read from the post for this record type. The first group is ordered by what a reader usually needs; the rest stays collapsed.
- Action
- accepted for review
- Decision maker
- National Medical Products Administration (国家药监局)
- Company
- Novo Nordisk
- Country
- China
Related decisions
Same kind only, ranked by embedding similarity to this record.